Janine Roney Unit Manager
Ph: 9076 6908
Dr Julian Elliott Head - Infectious Diseases Physician
Dr James McMahon Infectious Diseases Physician
Clinical Research Co-ordinators: Michelle Hagenauer, Mellissa Bryant, Sally Price, Jill Garlick, Cath Downs, Nigel Pratt, Jess Costa, Andrea Morrow
The Infectious Diseases Clinical Research Unit conducts single and multi-centre investigator and industry-initiated studies. The studies vary in type such as;
The unit is based at the Alfred Hospital, and enjoys close links with other primary and tertiary health care providers with similar inteests, including: Melbourne Sexual Health Centre, tRoyal Melbourne Hospital, Monash Health and inner city practices: Prahran Market, Centre and Northside Clinics. We also collaborate closely with the Burnet Institute, Monash University, The Doherty Institute, The Baker IDI and in Sydney, the Kirby Institute.
DIORR – Dolutegravir Impacts on Residual viral Replication. Randomised placebo controlled trial of adding 8 weeks Dolutegravir (or placebo) to regimen of 40 participants. Aims to understand impact of Dolutegravir on residual viral replication in people with longterm virological suppression. Main inclusions are VL < 50 for 3 years (one blip allowed), CD4 > 350 for 12 months and no history of exposure to any integrase inhibitors. Therefore study targets patients on PI or NNRTI based regimens.
MK-1439-018 (Doravirine) naïve study. Comparing Doravirine 100mg daily to Darunavir/ritonavir (800 mg/100 mg) daily with an investigator selected backbone of TDF/FTC or ABC/3TC in participants naïve to antiretroviral therapy. Primary endpoint after 48 weeks treatment.
MK-1439A-024 (Doravirine) switch study. Open label switch RCT to compare continuing current PI + 2NRTI containing antiretroviral regimen or switch to single tablet Doravirine/3TC/TDF in virologically suppressed participants. Participants must be receiving their first or second PI based regimen without a history of prior virological failure.
New Attachment Inhibitor for Heavily Treatment Experienced Patients. Multi-arm Phase 3 study in people with virological failure and limited treatment options due to multi-class resistance to add the new attachment inhibitor BMS-663068 to an optimized background regimen.
If you are interested in participating in a clinical study register your interest at firstname.lastname@example.org or phone 90766908
You can also be placed on a contact list for future studies.
All potential participants in a study are provided with a Patient Information and Consent Form and are encouraged to talk to either their physician or to a member of the Clinical Research Unit before agreeing to be involved in a study.
HIV cure in the media - how to sort fact from fiction
HIV_Cure_Media.pdf (207.1 KB)